Psychedelic study to test if 'Trip' or brain chemistry boosts mood

NCT ID NCT07360301

Not yet recruiting Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study will give psilocybin to 120 healthy adults with low well-being, either while awake or asleep, to see if the psychedelic experience is needed for mood benefits. Participants will also receive a placebo or clonidine for comparison. The goal is to understand how psilocybin works, not to treat a disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If successful, this study could help explain whether the psychedelic experience itself or direct brain effects improve well-being, pointing toward better mental health treatments.
What could go wrong: This is an early Phase 1 study with only 120 participants, so results may not apply broadly. The psychedelic experience can be intense and unpredictable, and the study hasn't started recruiting yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSYCHEDELIC EXPERIENCES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSYCHEDELIC EXPERIENCES WELL-BEING, PSYCHOLOGICAL

Contacts and locations

Locations

University of Wisconsin

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.